Drug products: Aphiahsone, Asmanex® Twisthaler®, Demoson, Elocom, Elocon®, Elosalic®, Mometason ABECE, Mometason Apofri, Mometason Glenmark, Mometason Orion, Mometasone Actavis, Mometasone Teva, Mommox, Nasomet, Nasonex, Nasonex®, Orimox, Ovixan
ATC code: D07AC13, D07XC03, R01AD09, R03BA07
Substances: mometasone, mometasone furoate, mometasone furoate monohydrate
Published randomized controlled studies on difference between men and women regarding mometasone efficacy in allergic rhinitis, asthma or dermatological conditions are lacking.
A randomized, double-blind, placebo-controlled study showed that mometasone nasal spray do not inhibit growth in children, neither in boys nor girls.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
Mometasone is a corticosteroid used in treatment of allergic rhinitis, asthma and dermatological conditions.
The systemic bioavailability of mometasone furoate 400 µg administrated as dry-powder inhaler has been evaluated in healthy volunteers in a randomized, open-label, crossover study (12 men, 12 women). There were no difference in mean absolute bioavailability between men and women (1.04% vs. 0.89%) .
No studies with a clinically relevant sex analysis regarding the effects of mometasone in allergic rhinitis, asthma or dermatologic conditions have been found.
The benefit of topical or systemic administration of corticosteroids in patients with olfactory dysfunction was evaluated in a retrospective nonrandomized study (46 men, 46 women). Patients were prescribed either mometasone nasal spray for 1-3 months or oral prednisolone for 21 days (starting dose 40 mg). Mometasone nasal spray did not improve olfactory function, while use of prednisolone led to improvement. Response to therapy was not related to patient’s sex, duration of disease or presence of parosmia dysfunction .
Systemic corticosteroids have been associated with inhibition of growth in children. The effect of mometasone nasal spray on growth in prepubertal children age 3-9 years with allergic rhinitis was evaluated in a randomized, double-blind, placebo-controlled trial (66 boys, 32 girls). In this study, after one year of treatment, mometasone did not retard growth, neither in girls nor in boys .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2016-09-15
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson